Overview

Phase 1 Study of LQT-1213 in Healthy Adults

Status:
Completed
Trial end date:
2023-03-05
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.
Phase:
Phase 1
Details
Lead Sponsor:
Thryv Therapeutics, Inc.